These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 18506211)

  • 21. A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2.
    Bernstein DI; Morello CS; Cardin RD; Bravo FJ; Kraynyak KA; Spector DH
    Vaccine; 2020 Jan; 38(1):79-89. PubMed ID: 31611098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Construction and Immunogenicity Analysis of Herpes Simplex Virus Type 2 Glycoprotein D Recombinant Adenovirus Vaccine].
    Liu W; Zhao D; Wang Z; Li Y; Wang H; Wang H
    Bing Du Xue Bao; 2016 May; 32(3):267-72. PubMed ID: 29962197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.
    Halford WP; Püschel R; Gershburg E; Wilber A; Gershburg S; Rakowski B
    PLoS One; 2011 Mar; 6(3):e17748. PubMed ID: 21412438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.
    Awasthi S; Zumbrun EE; Si H; Wang F; Shaw CE; Cai M; Lubinski JM; Barrett SM; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
    J Virol; 2012 Apr; 86(8):4586-98. PubMed ID: 22318147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs.
    McClements WL; Armstrong ME; Keys RD; Liu MA
    Vaccine; 1997 Jun; 15(8):857-60. PubMed ID: 9234533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.
    Awasthi S; Balliet JW; Flynn JA; Lubinski JM; Shaw CE; DiStefano DJ; Cai M; Brown M; Smith JF; Kowalski R; Swoyer R; Galli J; Copeland V; Rios S; Davidson RC; Salnikova M; Kingsley S; Bryan J; Casimiro DR; Friedman HM
    J Virol; 2014 Feb; 88(4):2000-10. PubMed ID: 24284325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection.
    Bernstein DI; Tepe ER; Mester JC; Arnold RL; Stanberry LR; Higgins T
    Vaccine; 1999 Apr; 17(15-16):1964-9. PubMed ID: 10217595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
    Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
    J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.
    Chiuppesi F; Vannucci L; De Luca A; Lai M; Matteoli B; Freer G; Manservigi R; Ceccherini-Nelli L; Maggi F; Bendinelli M; Pistello M
    J Virol; 2012 Jun; 86(12):6563-74. PubMed ID: 22491465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.
    Bernstein DI; Farley N; Bravo FJ; Earwood J; McNeal M; Fairman J; Cardin R
    Vaccine; 2010 May; 28(21):3748-53. PubMed ID: 19857450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs.
    Quenelle DC; Collins DJ; Rice TL; Prichard MN; Marciani DJ; Kern ER
    Antiviral Res; 2008 Nov; 80(2):223-4. PubMed ID: 18573279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
    Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
    J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
    J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
    Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL
    J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
    Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK
    Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
    Stanfield BA; Bravo FJ; Dixon DA; Chouljenko VN; Kousoulas KG; Bernstein DI
    Vaccine; 2022 Oct; 40(42):6093-6099. PubMed ID: 36114130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.
    Natuk RJ; Cooper D; Guo M; Calderon P; Wright KJ; Nasar F; Witko S; Pawlyk D; Lee M; DeStefano J; Tummolo D; Abramovitz AS; Gangolli S; Kalyan N; Clarke DK; Hendry RM; Eldridge JH; Udem SA; Kowalski J
    J Virol; 2006 May; 80(9):4447-57. PubMed ID: 16611905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.
    Jazayeri M; Soleimanjahi H; Fotouhi F; Pakravan N
    Comp Immunol Microbiol Infect Dis; 2009 Sep; 32(5):453-61. PubMed ID: 18571235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.